drugset / Trial / NCT05978544
Safety and Preliminary Clinical Activity of Itolizumab in ARDS
RandomizedSequentialOpen-labelTreatment
Summary
To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with acute respiratory distress syndrome (ARDS) caused by Infectious Pneumonia.
Timeline
- Start
- 2023-12-31
- Primary completion
- 2025-11-30
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itolizumab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Itolizumab | Monoclonal antibody | 150 mg | Intravenous |